Hologic, Inc. (Hologic or the
Company) HOLX, a leading developer, manufacturer and supplier of
premium diagnostics, medical imaging systems and surgical products dedicated
to serving the healthcare needs of women, today announced that it has entered
into a definitive agreement to sell its LIFECODES business unit to Immucor,
Inc.
Under the terms of the agreement, Hologic will receive $85 million in cash at
closing, subject to certain adjustments, and have the opportunity to earn a
contingent payment of $10 million based on achievement of certain financial
targets for the calendar year 2013.
The transaction is subject to customary closing conditions, including
expiration of the applicable waiting periods under the Hart-Scott-Rodino
Antitrust Improvements Act of 1976, as amended. The transaction is expected to
close during the second fiscal quarter.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsAsset Sales
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in